Last updated on May 2018

Denosumab Versus Bisphosphonates (Alendronate) in GIOP

Brief description of study

A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis

Detailed Study Description

Study design: an open-label randomized controlled trial Duration of study: 12 months

Treatment arms:

  1. Denosumab: a total of 2 doses in a period of 12 months
  2. Oral alendronate: weekly dose in a period of 12 months Target sample size: 220 patients (110 patients in each arm)

Clinical Study Identifier: NCT03005678

Find a site near you

Start Over